natgillin/translations-raw huggingface dataset:
you have an infection are fever, wounds, feeling tired, dental problems, a bad cough that lasts longer than 2 weeks, pain in the chest or coughing up blood or sputum.
zvišana telesna temperatura, rane, občutek utrujenosti, težave z zobmi, hud prehlad, ki traja dlje kot 2 tedna, bolečine v prsnem košu ali izkašljevanje krvi ali sputuma.
- If you have forms of psoriasis other than plaque psoriasis (for instance other more severe forms
- Če imate druge oblike psoriaze kot je psoriaza s plaki (na primer druge težje oblike psoriaze, ki
of psoriasis, as diagnosed by your doctor).
jih je ugotovil vaš zdravnik).
24 Take special care with Raptiva:
23 Bodite posebno pozorni pri uporabi zdravila Raptiva:
- If you experience hypersensitivity or allergic reactions such as overall body itching, hives, skin
- Če dobite preobčutljivostno ali alergijsko reakcijo, kot je srbenje celega telesa, urtikarijo,
flushing or rash tell your doctor immediately or go to the local casualty.
pordelost kože ali izpuščaj, takoj obvestite svojega zdravnika ali poiščite najbližjo nujno zdravniško pomoč.
- You might get infections more easily.
- Lahko boste bolj dovzetni za okužbe.
If you develop a new infection or notice any new or
Če razvijete novo okužbo ali opazite novo ali nenadno
sudden change in thinking, balance, strength, talking, walking or vision, please contact your doctor.
spremembo mišljenja, ravnotežja, moči, govora, hoje ali vida, se prosimo posvetujte z zdravnikom.
He/ she will determine whether to monitor your treatment or whether it is necessary for you to stop using Raptiva.
Zdravnik bo določil ali nadzorovati vaše zdravljenje ali pa je potrebno da prenehate z uporabo zdravila Raptiva.
- If you develop cancer while undergoing treatment, please contact your doctor who will
- Če se pri vas razvije rakasto obolenje med zdravljenjem z zdravilom Raptiva, se prosimo
determine if it is necessary for you to stop using Raptiva.
posvetujte z zdravnikom, ki bo določil, ali je potrebno da prenehate z uporabo zdravila Raptiva.
- If you develop signs and symptoms associated with anaemia (a reduction in red blood cells
- Če razvijete znake ali simptome povezane z anemijo (zmanjšanje števila rdečih krvnih celic, ki
which can make the skin pale and cause weakness or breathlessness) while undergoing treatment, please contact your doctor who will determine if it is necessary for you to stop using Raptiva.
lahko povzroči bledo polt, slabotnost ali zasoplost) med zdravljenjem z zdravilom Raptiva, se posvetujte z zdravnikom, ki bo določil, ali je potrebno da prenehate z uporabo zdravila Raptiva.
- If you develop any of the signs and symptoms associated with a decrease in blood platelets,
- Če razvijete kakršnekoli znake ali simptome povezane z zmanjšanjem števila trombocitov, kot
such as easy bleeding from the gums, bruising or pinpoint red spots on the skin, please tell your doctor immediately.
so nagnjenost h krvavitvam iz dlesni, modrice ali točkaste rdeče pike na koži, prosimo da nemudoma obvestite svojega zdravnika.
He/ she will determine whether to monitor your treatment or whether it is necessary for you to stop using Raptiva.
Zdravnik bo določil ali nadzorovati vaše zdravljenje ali pa je potrebno, da prenehate z uporabo zdravila Raptiva.
- Some patients had reactions including headache, fever, nausea and vomiting within two days of
- Nekateri bolniki so imeli reakcije, vključno z glavobolom, vročino, slabostjo in bruhanjem v
each of the first two injections.
roku dveh dni, po vsaki od prvih dveh injekcij.
- If you discontinue Raptiva treatment (and this applies especially to patients not responding to
- Če prekinete zdravljenje z Raptivo (in to še posebej velja za bolnike, ki se ne odzivajo na
treatment) your psoriasis may significantly worsen.
zdravljenje), se lahko vaša psoriaza pomembno poslabša.
- If you experience a worsening of your psoriasis or you develop arthritis, please inform your
- Če nastopi poslabšanje psoriaze ali razvijete artritis, se prosimo posvetujte s svojim zdravnikom.
He/ she will determine whether to stop using Raptiva or continue treatment with closer observation.
Zdravnik bo določil ali prekiniti z uporabo zdravila Raptiva ali nadaljevati zdravljenje z bolj tesnim nadzorom.
You must not receive
Med zdravljenjem z zdravilom
certain types of vaccines during Raptiva treatment.
Raptiva ne smete prejeti določenih vrst cepiv.
He/ she will calculate the
- Če se vaša telesna masa nepričakovano spremeni, se prosimo posvetujte z zdravnikom.
correct dosage based on your new weight.
Zdravnik bo izračunal pravilen odmerek zdravila na podlagi vaše nove telesne mase.
Please check with your doctor if you are planning to receive any vaccine (see “ Take special care with Raptiva”).
Posvetujte se z zdravnikom, če načrtujete cepljenje (glejte » Bodite posebno pozorni pri uporabi zdravila Raptiva «).
When taking Raptiva you might be more vulnerable to infections (see Take special care with Raptiva) this effect might be enhanced by other medicines that are used to treat psoriasis and that also make you more vulnerable to infections.
Ta vpliv lahko povečajo druga zdravila, ki se uporabljajo za zdravljenje psoriaze in tudi povečajo vašo dovzetnost za okužbe.
Pregnancy It is not known whether Raptiva can cause harm to your baby if you are pregnant or whether it can affect your ability to become pregnant.
Nosečnost Ni znano ali lahko zdravilo Raptiva škoduje otroku, če ste noseči in ali lahko vpliva na vašo zmožnost zanositve.
Breast-feeding It is possible that efalizumab is excreted in human milk.
Dojenje Možno je, da se efalizumab izloča v materino mleko.
25 Driving and using machines The use of Raptiva is not expected to affect your ability to drive and use machines.
24 Vpliv na sposobnost upravljanja vozil in strojev Ni pričakovati, da bi uporaba zdravila Raptiva vplivala na vašo sposobnost upravljanja vozil in strojev.
Dosing for adults (18-64 years) and the elderly (≥ 65 years) The usual dose is an initial single injection of 0.7 mg/ kg followed by weekly injections of 1.0 mg/ kg.
Odmerjanje za odrasle (18 - 64 let) in starejše (≥ 65 let) Običajen odmerek je enkratna začetna injekcija z 0, 7 mg/ kg, ki ji sledijo tedenske injekcije z 1, 0 mg/ kg.
Method and route of administration Raptiva is injected just under the skin (subcutaneous).
Način in pot uporabe Zdravilo Raptiva se injicira tik pod kožo (subkutano).
If you administer Raptiva, please read the following instructions carefully and follow then step by step: • Wash your hands.
Če si sami injicirate zdravilo Raptiva, prosimo, da natančno preberete naslednja navodila in jih nato upoštevate korak za korakom: • Umijte si roke.
It is important that your hands and items you use be as clean as possible. • Take the Raptiva out of the refrigerator and lay out on a clean surface everything you need: o one vial containing the Raptiva powder o one pre-filled syringe containing the solvent o one EasyMIX adapter for reconstitution o two alcohol swabs o one needle for subcutaneous injection, and o a sharps container
eno vialo z Raptiva praškom eno napolnjeno injekcijsko brizgo z vehiklom en adapter EasyMIX za rekonstitucijo dve alkoholni blazinici eno injekcijsko iglo za subkutano injiciranje in posodo za odlaganje ostrih predmetov.
Wipe the top of the vial with an alcohol swab. • Holding the EasyMIX outer cover, carefully peel back and remove the protective film using the tab.
Obrišite vrh viale z alkoholno blazinico. • Medtem ko držite zunanji pokrovček adapterja EasyMIX, previdno odlepite in odstranite zaščitno plast, tako da primete za jeziček.
You should not touch this area. • Holding the EasyMIX outer cover, place it on top of the vial, then press down so that the plastic spiked end pierces the rubber stopper on the vial. • Ensure the EasyMIX adapter is firmly attached to the vial, before removing the outer cover.
Konice se ne dotikajte. • Medtem ko držite zunanji pokrovček adapterja EasyMIX, ga položite na vrh viale, pritisnite navzdol, da plastična konica prebode gumijasti zamašek na viali. • Prepričajte se, da je adapter EasyMIX dobro pričvrščen na vialo, preden odstranite zunanji pokrovček.
26 • Pull off the cap covering the pre-filled syringe tip. • Attach the pre-filled syringe containing the solvent to the EasyMIX adapter with a ‘ push and twist’ action.
• Odtrgajte pokrovček, ki pokriva nastavek napolnjene injekcijske brizge. • Na adapter EasyMIX pritrdite napolnjeno injekcijsko brizgo z vehiklom, tako da pritisnete in obrnete.
• Very slowly push down on the syringe plunger to inject all the solvent into the Raptiva vial. • Without removing the syringe, gently rotate the vial to dissolve the medicine in the solvent.
25 • Zelo počasi pritisnite navzdol bat injekcijske brizge, da injicirate ves vehikel v vialo Raptiva. • Ne da bi odstranili injekcijsko brizgo, nežno zavrtite vialo, da raztopite zdravilo v vehiklu.
No other medicines should be added to the solution containing Raptiva and Raptiva should not be reconstituted with other solvents. • Turn the vial upside down, with the syringe still attached.
Nobenih drugih zdravil ne smete dodajati v raztopino z zdravilom Raptiva in zdravila Raptiva ne smete rekonstituirati z drugimi vehikli. • Obrnite vialo navzdol skupaj s pritrjeno injekcijsko brizgo.
With the syringe still attached to the vial, check the syringe for air bubbles. • Gently tap the syringe to make any bubbles rise to the top of the syringe.
Z injekcijsko iglo še vedno zapičeno v vialo, preverite če so v injekcijski brizgi zračni mehurčki. • Rahlo potrkajte po injekcijski brizgi, da se zračni mehurčki dvignejo proti vrhu brizge.
• Gently push the plunger up until the dose to be given remains in the syringe.
26 • Nežno pritiskajte bat kolikor je potrebno za nastavitev pravilnega odmerka.
• Check you have the right dose, then remove the syringe from the EasyMIX adapter using a ‘ twist and pull’ action.
• Preverite, da imate pravilen odmerek in odstranite injekcijsko brizgo z adapterja EasyMIX tako da pritisnete in obrnete.
27 You are now ready to attach the injection needle. • Take the injection needle and, with its shield still in place, carefully screw it on to the syringe tip.
Sedaj lahko pritrdite injekcijsko iglo. • Vzemite injekcijsko iglo in jo skupaj z varovalnim pokrovčkom previdno privijte na nastavek injekcijske brizge.
The injection sites should be rotated. • Wipe the chosen area with an alcohol swab.
Mesta za samoinjiciranje vključujejo zadnjico, stegna, trebuh ali zgornji del roke.
Remove the shield from the injection needle. • Immediately inject the solution as follows:
Mesta injiciranja morate izmenjavati. • Obrišite izbrano mesto z alkoholno blazinico.
Firmly pinch the skin together and insert the needle at a 45° to 90° angle using a dart-like motion.
Iz injekcijske igle ostranite varovalni pokrovček. • Takoj injicirajte raztopino, kot je opisano: trdno stisnite kožo skupaj in z gibom podobnim metu sulice, zabodite iglo pod kotom 45° do 90°.
Immediately withdraw the needle and clean the skin with an alcohol swab using a circular motion.
Vzemite si dovolj časa, da injicirate vso raztopino. Takoj izvlecite injekcijsko iglo in s krožnimi gibi očistite kožo z alkoholno blazinico.
• Dispose of all used items:
27 • Odstranite vse uporabljene predmete:
Once you have finished your injection, immediately discard all needles and empty glass containers in a sharps container.
Ko ste zaključili z injiciranjem, takoj odstranite vse igle in prazne steklene vsebnike v posodo za ostre predmete.
If you use more Raptiva than you should If you have injected more Raptiva than told by your doctor, please contact your doctor or pharmacist.
Če ste uporabili večji odmerek zdravila Raptiva, kot bi smeli Če ste si injicirali več zdravila Raptiva kot vam je predpisal zdravnik, se prosimo posvetujte z zdravnikom ali s farmacevtom.
If you forget to use Raptiva Do not take a double dose to make up for a forgotten dose.
Če ste pozabili uporabiti zdravilo Raptiva Ne uporabite dvojnega odmerka, da bi nadomestili izpuščeni odmerek.
(See “ Take special care with Raptiva”)
Če ste prenehali uporabljati zdravilo Raptiva Če prekinete zdravljenje z zdravilom Raptiva brez nadomestnega zdravljenja, se lahko vaši simptomi psoriaze pomembno poslabšajo (glejte » Bodite posebno pozorni pri uporabi zdravila Raptiva «).
(See also under Take Special Care with Raptiva)
Vaš zdravnik vam bo svetoval kaj storiti v primeru nezadostnega odziva ali poslabšanja bolezni (glejte tudi » Bodite posebno pozorni pri uporabi zdravila Raptiva «).
For this purpose the following classification has been used: • Very common:
V ta namen smo uporabili naslednjo klasifikacijo:
Side effects that may occur in more than 1 out of 10 patients; • Common:
- Zelo pogosti: neželeni učinki, ki se lahko pojavijo pri več kot 1 od 10 bolnikov;
Side effects that may occur in 1 to 10 out of 100 patients; • Uncommon:
- Pogosti: neželeni učinki, ki se lahko pojavijo pri 1 do 10 bolnikov od 100 bolnikov;
Side effects that may occur in 1 to 10 out of 1,000 patients; • Rare:
- Občasni: neželeni učinki, ki se lahko pojavijo pri 1 do 10 bolnikov od 1. 000 bolnikov;
Side effects that may occur in 1 to 10 out of 10,000 patients; • Very rare:
- Redki: neželeni učinki, ki se lahko pojavijo pri 1 do 10 bolnikov od 10. 000 bolnikov;
Side effects that may occur in less than 1 out of 10,000 patients;
- Zelo redki: neželeni učinki, ki se lahko pojavijo pri manj kot 1 bolniku od 10. 000 bolnikov;
Tell your doctor or go to the local casualty and stop using Raptiva immediately if you: • Notice serious hypersensitivity or allergic reactions, such as anaphylaxis.
28 Obvestite svojega zdravnika ali poiščite najbližjo nujno zdravniško pomoč in takoj prenehajte z uporabo zdravila Raptiva, če:
Symptoms of an allergic reaction are common and generally include overall body itching, hives, skin flushing or rash.
alergijske reakcije so pogosti in na splošno vključujejo srbenje celega telesa, urtikarijo, rdečico kože ali izpuščaj.
Prompt medical care is needed since serious allergic reactions may be potentially life-threatening. • Notice symptoms of low blood platelet counts, such as easy bleeding from the gums, bruising or pinpoint red spots on the skin.
Takoj je potrebna nujna zdravniška pomoč, ker so lahko hude alergijske reakcije potencialno življenje ogrožajoče.
These symptoms are uncommon. • Notice signs of nerve disorder such as tingling or onset of weakness in legs or arms or new or sudden change in thinking, balance, strength, talking, walking or vision. • Notice severe headache accompanied with nuchal rigidity.
- Opazite simptome nizkega števila trombocitov, kot so nagnjenost h krvavitvam iz dlesni,
This may occur rarely in particular at the beginning of the treatment. • Are diagnosed with cancer. • Develop a diffuse skin rash or blisters in your oral cavity.
Obvestite svojega zdravnika in se pogovorite z njim o vašem splošnem zdravstvenem stanju, če opazite karkoli od naslednjega:
Tell your doctor and discuss with him your general health if you notice any of the following: • Back pain, joints pain, headache, vomiting, weakness, fatigue or rash.
Ni
These common side effects have not been clearly associated with Raptiva but have been observed when using it.
jasne povezave med temi pogostimi neželenimi učinki in zdravilom Raptiva, vendar so bili opaženi med njeno uporabo.
Your doctor may want to examine you more closely and ask you to have blood tests. • Fever or if you think that you have an infection.
Zdravilo Raptiva deluje na
Raptiva acts on the immune system, which may potentially increase your risk of infectious diseases or may reactivate old infections.
Okužbe so zelo pogoste.
Infections are very common. • A relapse or flare or strong worsening of psoriasis or red, inflamed psoriatic plaques, sometimes with swelling of your arms or legs or joint inflammation, especially after stopping Raptiva.
- Relaps (ponovitev) ali zagon ali močno poslabšanje psoriaze ali rdeči, vnetni psoriazni plaki,
These side effects are common. • Shortness of breath or any persistent respiratory difficulties. • Signs of facial paralysis usually on one side of the face (such as weakness of face muscles and dribbling) possibly preceded by pain in the ear area.
Ti neželeni učinki so pogosti.
Generally patients with facial paralysis recover within a few weeks without any specific treatment.
- Kratko sapo ali kakršne koli vztrajne težave z dihanjem.
HOW TO STORE RAPTIVA
SHRANJEVANJE ZDRAVILA RAPTIVA
To maintain sterility, Raptiva must be used immediately after first opening and reconstitution.
29 Za vzdrževanje sterilnosti morate zdravilo Raptiva uporabiti takoj po prvem odprtju ovojnine in rekonstituciji.
What Raptiva contains • The active substance is efalizumab, each vial contains a deliverable dose of 125 mg efalizumab. • The other ingredients are polysorbate 20, histidine, histidine hydrochloride monohydrate and sucrose. • Each pre-filled syringe of solvent contains sufficient water for injections to make up the solution for injection.
Kaj vsebuje zdravilo Raptiva • Zdravilna učinkovina je efalizumab, vsaka viala vsebuje razpoložljiv odmerek 125 mg efalizumaba. • Pomožne snovi so polisorbat 20, histidin, histidinijev klorid monohidrat in saharoza. • Vsaka napolnjena injekcijska brizga z vehiklom vsebuje zadostno količino vode za injekcije za pripravo raztopine za injiciranje.
What Raptiva looks like and contents of the pack Raptiva is presented as a powder and solvent for solution for injection.
Izgled zdravila Raptiva in vsebina pakiranja Zdravilo Raptiva je v obliki praška in vehikla za raztopino za injiciranje.
The product is supplied in packs of 1 vial of powder, 1 pre-filled syringe of solvent, 1 EasyMIX adapter for reconstitution, 1 needle for injection; in packs of 4 vials of powder, 4 pre-filled syringes of solvent, 4 EasyMIX adapters for reconstitution, 4 needles for injection and in packs of 12 vials of powder, 12 pre-filled syringes of solvent, 12 EasyMIX adapters for reconstitution and 12 needles for injection.
Zdravilo je na voljo v pakiranju z 1 vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapterjem EasyMIX za rekonstitucijo in 1 injekcijsko iglo za injiciranje, v pakiranju s 4 vialami s praškom, 4 napolnjenimi injekcijskimi brizgami z vehiklom, 4 adapterji EasyMIX za rekonstitucijo in 4 injekcijskimi iglami za injiciranje in v pakiranju z 12 vialami s praškom, 12 napolnjenimi injekcijskimi brizgami z vehiklom, 12 adapterji EasyMIX za rekonstitucijo in 12 injekcijskimi iglami za injiciranje.
Marketing Authorisation Holder Serono Europe Ltd.
Imetnik dovoljenja za promet z zdravilom Serono Europe Ltd.
Manufacturer Merck Serono S. p. A.
Izdelovalec Industria Farmaceutica Serono S. p. A.
Via Luigi Einaudi 11 00012 Guidonia Montecelio/ Rome Italy
Via Luigi Einaudi 11 00012 Guidonia Montecelio/ Rim Italija
Malta Cherubino Ltd Delf Building Sliema Road MT-GZR 06 Gzira Malta Tel: +356-21-343270/ 1/ 2/ 3/ 4
30 Malta Česká republika Cherubino Ltd Merck spol. s. r. o Delf Building Zděbradská 72 Sliema Road CZ- 251 01 Říčany - Jažlovice MT- GZR 06 Gzira Malta Tel. +420 323619211 Tel: +356- 21- 343270/ 1/ 2/ 3/ 4
Slovenská republika Merck spol. s r. o.
31 Slovenská republika Ísland Merck spol. s r. o.
Rasilez is a medicine containing the active substance aliskiren.
Rasilez je zdravilo, ki vsebuje zdravilno učinkovino aliskiren.
Rasilez is used to treat essential hypertension (high blood pressure). ‘ Essential ’ means that no specific cause for the hypertension can be found.
Zdravilo Rasilez se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka).
The recommended dose of Rasilez is 150 mg once a day, either taken alone or in combination with other medicines for hypertension.
Priporočeni odmerek zdravila Rasilez znaša 150 mg enkrat dnevno, bodisi samostojno ali v kombinaciji z drugimi zdravili za zdravljenje hipertenzije.
Rasilez is not recommended for children, due to a lack of information on safety and effectiveness in this group.
Zdravilo Rasilez ni priporočeno za otroke, zaradi pomanjkanja podatkov o varnosti in učinkovitosti v tej skupini.
The effects of Rasilez were first tested in experimental models before being studied in humans.
Učinki zdravila Rasilez so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
Rasilez was studied in 14 main studies involving over 10,000 patients with essential hypertension.
Zdravilo Rasilez so raziskali v 14 glavnih študijah, ki so vključevale preko 10. 000 bolnikov z esencialno hipertenzijo.
Rasilez, taken alone or in combination with other medicines, was also compared with other medicines for hypertension.
Zdravilo Rasilez so, bodisi kot samostojno zdravilo ali v kombinaciji z drugimi zdravili, primerjali tudi z drugimi zdravili za zdravljenje hipertenzije.
Combination studies looked at Rasilez used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
V študijah kombinacij zdravil so raziskovali 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged diuretic (hydrochlorothiazide).
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged zdravilo Rasilez v kombinaciji z zaviralcem angiotenzinske konvertaze (ramipril), zaviralcem angiotenzinskih receptorjev (valsartan), zaviralcem receptorjev beta (atenolol), zaviralcem kalcijevih kanalčkov (amlodipin) in diuretikom (hidroklorotiazid).
Rasilez on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure.
Zdravilo Rasilez kot samostojno zdravilo je bilo pri zdravljenju visokega krvnega tlaka bolj učinkovito kot placebo in enako učinkovito kot zdravljenja s primerljivimi zdravili.
When the results of the five studies comparing Rasilez taken alone with placebo were looked at together, patients aged under 65 had an average fall in diastolic blood pressure of 9.0 mmHg after eight weeks of taking 150 mg Rasilez, from an average of 99.4 mmHg at the start of the study.
Ko so primerjali skupaj rezultate petih študij, v katerih so zdravilo Rasilez kot samostojno zdravilo primerjali s placebom, se je pri bolnikih pod 65 leti starosti po osmih tednih jemanja 150 mg zdravila Rasilez povprečni diastolični tlak, ki je na začetku znašal 99, 4 mmHg, v povprečju znižal za 9, 0 mmHg.
Larger falls were seen in patients aged 65 or over and those taking higher doses of Rasilez.
Pri bolnikih, starih 65 let ali več, in tistih, ki so jemali večje odmerke zdravila Rasilez, so opazili večja znižanja tlaka.
Rasilez also reduced blood pressure in patients with diabetes, patients who were overweight, and those who were over 65 years of age.
Zdravilo Rasilez je krvni tlak znižalo tudi pri bolnikih s sladkorno boleznijo, prekomerno težkih bolnikih in tistih, ki so bili starejši od 65 let.
The studies also showed that Rasilez, when taken in combination with other medicines (especially hydrochlorothiazide), can produce additional decreases in blood pressure compared with those produced by these medicines taken without Rasilez.
Študije so pokazale tudi, da lahko zdravilo Rasilez v kombinaciji z drugimi zdravili (še posebej hidroklorotiazidom) povzroči še dodatna znižanja krvnega tlaka v primerjavi z znižanji tlaka, ki jih imajo ta zdravila brez kombiniranja z zdravilom Rasilez.
The most common side effect with Rasilez (seen in between 1 and 10 patients in 100) is diarrhoea.
Najpogostejši neželeni učinek zdravila Rasilez (opažen med 1 in 10 bolniki od 100) je driska.
For the full list of all side effects reported with Rasilez, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rasilez, glejte Navodilo za uporabo.